New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Pennsylvania’s short-term politics threaten its biotech future, driving innovation and opportunity to rival states.

CereCura was co-founded by renowned scientist and UBC professor Pieter Cullis, who developed LNPs, the drug delivery system ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; ...

Economic cost of L.A. wildfires expected to keep rising, Bezos suffers rocket launch setback in space race with Musk, more news to start your day. The Edge specializes in special situations such as ...